Skip to content

Main Navigation

  • About us
    • History
    • Mission, vision & values
    • Leadership
    • Scientific advisors
    • Our team
    • Social impact (CSR)
  • Science & Services
    • Contexts of use
      • Trial design and analyses
      • Program strategies and efficiencies
      • Special/specific populations
      • Special considerations
      • Regulatory interactions
    • Pharmetheus Platforms
      • Model-Informed Drug Development
      • PBPK & PBBM
      • Pharmacometrics
      • QSP
    • Solutions
      • Milestone Analysis
      • Embedded Scientist
      • Expert Advice
      • Training workshop
      • Scientific Publication
    • Specific services
      • Model-Informed Bioequivalence & Biosimilarity
    • Publications
    • Case studies
  • Careers
    • Working with us
    • Open positions
    • Employee stories
  • Events
  • News
  • Contact us
  • LinkedIn

A Bayesian-NLME approach identifies patients at risk of delayed MTX elimination if informative TDM data is provided

PAGE 33 (2025) Abstr 11507
Klose M, Marschner D, Knott M, Wendler J, Müller-Kühnle J, Kovar L, Huisinga W, Nyhoegen C, Michelet R, Mc Laughlin AM, Illerhaus G, Kloft C.
ConferenceMethodologyOncologyPharmacometricsTrial design and analysis

Pharmetheus Affiliates

Portrait-of-Anna-Mc-Laughlin_Pharmetheus
Senior Director, MIDD Consultant

Anna Mc Laughlin

See bio

Contact

Pharmetheus AB
Kungsängstull 4
753 19 Uppsala, Sweden

Visiting address: Dragarbrunnsgatan 77, 5th floor

info@pharmetheus.com

+46(0)18-51 33 28

Links

  • Home
  • Newsletter
  • LinkedIn
  • Whistleblower
  • Privacy Policy
  • Cookie Policy
  • Consent Preferences

Services

  • Contexts of use
  • Pharmetheus platforms
  • Solutions
  • Case studies
  • Publications

About

Pharmetheus is a consultancy firm helping clients reduce uncertainty in technical and regulatory processes, increasing confidence in the development of new medicines that can improve patients’ lives.